Crinetics’ carcinoid syndrome drug gears up for registrational test after PhII data update

Cri­net­ics Phar­ma­ceu­ti­cals of­fered new in­sight in­to its Phase II drug pal­tuso­tine in ad­dress­ing car­ci­noid syn­drome symp­toms, set­ting plans in mo­tion fur­ther for a reg­is­tra­tional tri­al to start by the end of the year.

The com­pa­ny’s Tues­day da­ta re­lease builds up­on what it tout­ed in De­cem­ber, when it said that its so­mato­statin re­cep­tor type 2 (SST2) ag­o­nist of­fered “sig­nif­i­cant re­duc­tions in fre­quen­cy and in­ten­si­ty” of flush­ing episodes and bow­el move­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.